keyword
MENU ▼
Read by QxMD icon Read
search

HSDD

keyword
https://www.readbyqxmd.com/read/29278235/role-of-hormones-in-hypoactive-sexual-desire-disorder-and-current-treatment
#1
Ahmed AlAwlaqi, Houda Amor, Mohamed E Hammadeh
Over the decades, female sexual dysfunction (FSD) has grown to be an increasingly potential problem that complicates the quality of life among women. In the current review, FSD refers to recurrent and persistent problems with sexual orgasm, desire, or response. One of the most common subtypes of FSD that has evoked increased research interest in the scientific community is hyposexuality. Today, there is a consensus that hyposexuality is a multifactorial condition that manifests with reduced sexual desire resulting in significant interpersonal distress...
December 15, 2017: Journal of the Turkish German Gynecological Association
https://www.readbyqxmd.com/read/29198512/understanding-the-role-of-serotonin-in-female-hypoactive-sexual-desire-disorder-and-treatment-options
#2
REVIEW
Harry A Croft
BACKGROUND: The neurobiology of sexual response is driven in part by dopamine and serotonin-the former modulating excitatory pathways and the latter regulating inhibitory pathways. Neurobiological underpinnings of hypoactive sexual desire disorder (HSDD) are seemingly related to overactive serotonin activity that results in underactive dopamine activity. As such, pharmacologic agents that decrease serotonin, increase dopamine, or some combination thereof, have therapeutic potential for HSDD...
December 2017: Journal of Sexual Medicine
https://www.readbyqxmd.com/read/29172782/efficacy-of-tribulus-terrestris-for-the-treatment-of-premenopausal-women-with-hypoactive-sexual-desire-disorder-a-randomized-double-blinded-placebo-controlled-trial
#3
Fabiene Bernardes Castro Vale, Karla Zanolla Dias de Souza, Camilla Russi Rezende, Selmo Geber
Although hypoactive sexual desire disorder (HSDD) is the most common sexual complaint, there is no consensus for the ideal treatment. Our study aimed to evaluate the efficacy of treating premenopausal women with HSDD with Tribulus terrestris and its effect on the serum levels of testosterone. We performed a prospective, randomized, double-blind, placebo-controlled trial, with 40 premenopausal women reporting diminished libido, receiving T. terrestris or placebo. The questionnaires FSFI and the QS-F were used to evaluate sexual dysfunction before and after treatment...
November 27, 2017: Gynecological Endocrinology
https://www.readbyqxmd.com/read/29095039/women-with-hypoactive-sexual-desire-disorder-versus-sexual-interest-arousal-disorder-an-empirical-test-of-raising-the-bar
#4
Julia I O'Loughlin, Rosemary Basson, Lori A Brotto
In 2013, the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) was published with a major revision to the sexual dysfunction categories, and the diagnosis of female hypoactive sexual desire disorder (HSDD) was replaced with female sexual interest/arousal disorder (SIAD). Since being introduced, concern has been expressed that SIAD inappropriately "raises the bar" for diagnosis. To address these concerns, we sought to evaluate the number of women with a diagnosis of HSDD who also met criteria for SIAD...
November 2, 2017: Journal of Sex Research
https://www.readbyqxmd.com/read/29066935/female-sexual-dysfunction-a-focus-on-flibanserin
#5
REVIEW
Nicole M Lodise
Flibanserin is the first US Food and Drug Administration (FDA)-approved option for sexual dysfunction, specifically low sexual desire. Until recently, there were no FDA-approved medication options to assist the ~40% of women affected by female sexual dysfunction (FSD). Often, patients report feeling uncomfortable discussing sexual health, identifying a strong need for health care professionals (HCPs) to proactively reach out to patients to identify concerns and initiate a discussion about sexual health and the available treatment options...
2017: International Journal of Women's Health
https://www.readbyqxmd.com/read/29066307/aromatase-inhibitors-are-associated-with-low-sexual-desire-causing-distress-and-fecal-incontinence-in-women-an-observational-study
#6
Penelope J Robinson, Robin J Bell, Marie K Christakis, Stephanie R Ivezic, Susan R Davis
BACKGROUND: Little is known of the impact of aromatase inhibitor (AI) therapy on sexual and pelvic floor function. AIM: To document the prevalence of, and factors associated with, low desire, sexually related personal distress, hypoactive sexual desire dysfunction (HSDD), and pelvic floor dysfunction in women 10 years after breast cancer diagnosis. METHODS: This was a prospective, observational, community-based cohort study of Australian women with invasive breast cancer recruited within 12 months of diagnosis...
December 2017: Journal of Sexual Medicine
https://www.readbyqxmd.com/read/28993148/the-sexual-event-diary-sed-development-and-validation-of-a-standardized-questionnaire-for-assessing-female-sexual-functioning-during-discrete-sexual-events
#7
Yvonne van Nes, Jos Bloemers, Peter G M van der Heijden, Kim van Rooij, Jeroen Gerritsen, Rob Kessels, Leonard DeRogatis, Adriaan Tuiten
BACKGROUND: The efficacy of on-demand drugs for hypoactive sexual desire disorder (HSDD) or female sexual interest/arousal disorder (FSIAD) should be assessed using a validated instrument that assesses the discrete sexual events during which the on-demand drug is taken. AIM: To develop and validate an event log for measuring sexual satisfaction and sexual functioning of discrete sexual events. METHODS: Psychometric assessment was carried out on data of 10,959 Sexual Event Diaries (SEDs) collected during three clinical trials in a total of 421 women with HSDD...
November 2017: Journal of Sexual Medicine
https://www.readbyqxmd.com/read/28923310/factors-associated-with-specific-diagnostic-and-statistical-manual-of-mental-disorders-fourth-edition-sexual-dysfunctions-in-breast-cancer-survivors-a-study-of-patients-and-their-partners
#8
Susanna B Hummel, Daniela E E Hahn, Jacques J D M van Lankveld, Hester S A Oldenburg, Eva Broomans, Neil K Aaronson
BACKGROUND: Many women develop sexual problems after breast cancer (BC) treatment. Little is known about BC survivors with a Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) sexual dysfunction and their partners, and the factors associated with their sexual functioning. AIM: To evaluate (i) patient-related and clinical factors associated with (a) specific DSM-IV sexual dysfunctions and (b) level of sexual functioning and sexual distress as reported by BC survivors and (ii) the association between the sexual functioning of BC survivors and that of their partners...
October 2017: Journal of Sexual Medicine
https://www.readbyqxmd.com/read/28918588/a-practical-approach-to-managing-hypoactive-sexual-desire-disorder-in-women-with-diabetes
#9
REVIEW
Charmaine Rochester-Eyeguokan, Lisa Meade
Female sexual dysfunction (FSD) is highly prevalent in women with diabetes mellitus (DM), yet it remains unaddressed, undiagnosed, and untreated. Hypoactive sexual desire disorder (HSDD) is the most common complaint among women with FSD, but there is a paucity of research into its multifactorial etiology. Flibanserin is the only therapy approved by the US Food and Drug Administration for treating acquired, generalized HSDD in premenopausal women. Women with DM diagnosed with HSDD may require a multidisciplinary approach for optimal management...
October 2017: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/28865901/neuroimaging-of-female-sexual-desire-and-hypoactive-sexual-desire-disorder
#10
REVIEW
Stephanie Cacioppo
INTRODUCTION: Recent advances in neuroimaging offer an unprecedented window into the female sexual brain. The small samples and poor statistical power of individual functional magnetic resonance imaging studies have limited what can be gleaned about the systematic brain network that is involved in female sexual desire and female sexual dysfunction (eg, hypoactive sexual desire disorder [HSDD]). AIM: To quantitatively determine the brain network involved in HSDD...
August 30, 2017: Sexual Medicine Reviews
https://www.readbyqxmd.com/read/28817365/effect-of-flibanserin-treatment-on-body-weight-in-premenopausal-and-postmenopausal-women-with-hypoactive-sexual-desire-disorder-a-post-hoc-analysis
#11
Susan G Kornstein, James A Simon, Stuart C Apfel, James Yuan, Krista A Barbour, Robert Kissling
BACKGROUND: Flibanserin, a 5-HT1A agonist and 5-HT2A antagonist, is indicated for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. This post hoc analysis evaluated the effect of flibanserin treatment on body weight in premenopausal and postmenopausal women with HSDD. MATERIALS AND METHODS: This analysis included three 24-week, double-blind, placebo-controlled studies of flibanserin 100 mg each bedtime (qhs) in premenopausal women, a similarly designed study in postmenopausal women, and a 52-week, open-label extension study in premenopausal women...
November 2017: Journal of Women's Health
https://www.readbyqxmd.com/read/28814122/flibanserin-toxicity-in-a-toddler-following-ingestion
#12
Nicholas Granzella, Betty C Chen, Geoffrey S Baird, Matthew Valento
INTRODUCTION: Flibanserin is a medication recently approved by the FDA for treatment of generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Its mechanism of action is not fully understood but is thought to modulate serotonin receptors and increase levels of norepinephrine and dopamine. While much is known about toxicity of other drugs which affect these systems, there is little information about toxicity of flibanserin at this time. CASE: We present a case of a 2-year-old boy who ingested an estimated 600 mg of his mother's flibanserin...
August 17, 2017: Clinical Toxicology
https://www.readbyqxmd.com/read/28608926/the-pharmacodynamic-effects-of-combined-administration-of-flibanserin-and-alcohol
#13
D M Stevens, J M Weems, L Brown, K A Barbour, S M Stahl
WHAT IS KNOWN AND OBJECTIVE: Flibanserin is a serotonin 5-HT1A agonist and 5-HT2A antagonist approved for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Because of the increased risk of hypotension- and syncope-related adverse events (AEs) observed with coadministration of flibanserin and alcohol, alcohol use is contraindicated. To provide a more comprehensive understanding of the interaction between flibanserin and alcohol, the results of a dedicated phase 1 alcohol-interaction study and a pooled analysis of phase 3 studies of premenopausal women with HSDD are presented...
June 13, 2017: Journal of Clinical Pharmacy and Therapeutics
https://www.readbyqxmd.com/read/28583342/flibanserin-in-postmenopausal-women-with-hypoactive-sexual-desire-disorder-results-of-the-plumeria-study
#14
David J Portman, Louise Brown, James Yuan, Robert Kissling, Sheryl A Kingsberg
BACKGROUND: Hypoactive sexual desire disorder (HSDD) is a common sexual disorder in younger and older women. Flibanserin is approved for the treatment of acquired generalized HSDD in premenopausal women only. The efficacy of flibanserin for postmenopausal women with HSDD was demonstrated in the first of two North American randomized, double-blinded, placebo-controlled trials (SNOWDROP). AIM: To evaluate the safety and efficacy of flibanserin in postmenopausal women with HSDD in a second randomized, double-blinded, placebo-controlled trial (PLUMERIA)...
June 2017: Journal of Sexual Medicine
https://www.readbyqxmd.com/read/28499520/prevalence-and-predictors-of-low-sexual-desire-sexually-related-personal-distress-and-hypoactive-sexual-desire-dysfunction-in-a-community-based-sample-of-midlife-women
#15
Roisin Worsley, Robin J Bell, Pragya Gartoulla, Susan R Davis
BACKGROUND: Low desire is the most common sexual problem in women at midlife. Prevalence data are limited by lack of validated instruments or exclusion of un-partnered or sexually inactive women. AIM: To document the prevalence of and factors associated with low desire, sexually related personal distress, and hypoactive sexual desire dysfunction (HSDD) using validated instruments. METHODS: Cross-sectional, nationally representative, community-based sample of 2,020 Australian women 40 to 65 years old...
May 2017: Journal of Sexual Medicine
https://www.readbyqxmd.com/read/28442935/new-developments-in-the-treatment-of-hypoactive-sexual-desire-disorder-a-focus-on-flibanserin
#16
REVIEW
Christopher J Jayne, Michael J Heard, Sarah Zubair, Dustie L Johnson
The objective of the authors is to highlight the historical complexities for the diagnosis and treatment of hypoactive sexual desire disorder (HSDD) with a focus on Flibanserin. A systematic review of the medical literature published in PubMed using the search terms HSDD and Flibanserin was conducted. Each author reviewed the results of the systematic review for articles to include in this study. HSDD is defined as a persistent or recurrent deficiency or absence of sexual fantasies and desire for sexual activity causing marked distress or interpersonal difficulty that is not better accounted for by another diagnosis...
2017: International Journal of Women's Health
https://www.readbyqxmd.com/read/28434386/flibanserin-the-female-viagra
#17
Desiree Shapiro, Deanna Stevens, Stephen M Stahl
This article provides a clinically relevant review of the first medication approved by the US Food and Drug Administration for hypoactive sexual desire disorder (HSDD) in premenopausal women. In this short piece, the human sexual response cycle and its relevance to HSDD will be described as well as the pharmacological mechanism of action of flibanserin. Finally, efficacy and safety data of this new medication will be summarised.
April 24, 2017: International Journal of Psychiatry in Clinical Practice
https://www.readbyqxmd.com/read/28397671/-flibanserin-as-pharmacological-therapy-of-inhibited-sexual-desire-in-women
#18
Anne Sofie Eldon, Annamaria Giraldi
Flibanserin was approved by the Food and Drug Administration in the USA in August 2015 as the first drug for the treatment of American women with the dysfunction hypoactive sexual desire disorder (HSDD) and is a 5-HT1A agonist and 5-HT2A antagonist. The neurophysiological effects of flibanserin on these receptors are consistent with the clinical effects, i.e. significantly increasing sexual desire and frequency of satisfying sexual experiences. As such, shifting the balance between inhibitory and excitatory neurotransmitters of importance to sexual desire, flibanserin pharmacologically broaches a possible new approach to the treatment of HSDD...
February 13, 2017: Ugeskrift for Laeger
https://www.readbyqxmd.com/read/28364864/evaluation-of-the-efficacy-and-safety-of-tribulus-terrestris-in-male-sexual-dysfunction-a-prospective-randomized-double-blind-placebo-controlled-clinical-trial
#19
RANDOMIZED CONTROLLED TRIAL
Zdravko Kamenov, Svetlana Fileva, Krassimir Kalinov, Emmanuele A Jannini
OBJECTIVE: The primary objectives were to compare the efficacy of extracts of the plant Tribulus terrestris (TT; marketed as Tribestan), in comparison with placebo, for the treatment of men with erectile dysfunction (ED) and with or without hypoactive sexual desire disorder (HSDD), as well as to monitor the safety profile of the drug. The secondary objective was to evaluate the level of lipids in blood during treatment. PARTICIPANTS AND DESIGN: Phase IV, prospective, randomized, double-blind, placebo-controlled clinical trial in parallel groups...
May 2017: Maturitas
https://www.readbyqxmd.com/read/28337949/efficacy-of-metacognitive-therapy-for-hypoactive-sexual-desire-disorder-among-iranian-couples
#20
Mohammad Arash Ramezani, Khodabakhsh Ahmadi, Mohammadali Besharat, Sima Noohi, Afagh Ghaemmaghami
OBJECTIVE: The aim of present study was to compare the efficacy of metacognitive therapy (MCT) against Masters-Johnson sex therapy (MJST) for hypoactive sexual desire disorder (HSDD) in Iranian couples. METHODS: A randomized treatment trial was conducted. Participants were recruited from the family counseling clinics in Tehran and Isfahan. All were suffering from HSDD as defined by DSM-IV-R criteria. They were assigned randomly to two groups that received 10 sessions of either MCT or MJST...
March 24, 2017: Psychotherapy Research: Journal of the Society for Psychotherapy Research
keyword
keyword
114579
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"